Elisabeth Crönert-Bendell
Corporate Officer/Principal at RHYTHM PHARMACEUTICALS, INC.
Profile
Elisabeth Crönert-Bendell is currently the Senior Vice President & Head-Strategy at Rhythm Pharmaceuticals, Inc. She previously worked as a Senior Vice President at Sanofi and as the Head-Neuroscience Business Franchise at Kyowa Kirin International Plc.
Dr. Crönert-Bendell holds an MBA from INSEAD.
Elisabeth Crönert-Bendell active positions
Companies | Position | Start |
---|---|---|
RHYTHM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2021-03-31 |
Former positions of Elisabeth Crönert-Bendell
Companies | Position | End |
---|---|---|
SANOFI | Corporate Officer/Principal | - |
Kyowa Kirin International Plc
Kyowa Kirin International Plc Pharmaceuticals: MajorHealth Technology Kyowa Kirin International Plc is a specialty pharmaceutical company, which engages in the development and commercialization of prescription medicines for the treatment of unmet therapeutic needs in major markets. It offers Sancuso, a prescription medicine used to prevent nausea and vomiting in people receiving some types of chemotherapy treatment and Abstral, a medicine used in the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. The company was founded in 1995 and is headquartered in Galashiels, the United Kingdom. | Corporate Officer/Principal | - |
Training of Elisabeth Crönert-Bendell
INSEAD | Masters Business Admin |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
SANOFI | Health Technology |
RHYTHM PHARMACEUTICALS, INC. | Health Technology |
Private companies | 1 |
---|---|
Kyowa Kirin International Plc
Kyowa Kirin International Plc Pharmaceuticals: MajorHealth Technology Kyowa Kirin International Plc is a specialty pharmaceutical company, which engages in the development and commercialization of prescription medicines for the treatment of unmet therapeutic needs in major markets. It offers Sancuso, a prescription medicine used to prevent nausea and vomiting in people receiving some types of chemotherapy treatment and Abstral, a medicine used in the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. The company was founded in 1995 and is headquartered in Galashiels, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Elisabeth Crönert-Bendell